ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / Common Stock
Shares outstanding
98,294,118
Total 13F shares
55,071,412
Share change
+1,651,559
Total reported value
$368,976,724
Put/Call ratio
52%
Price per share
$6.70
Number of holders
92
Value change
+$11,246,123
Number of buys
62
Number of sells
47

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) as of Q2 2023

As of 30 Jun 2023, ARS Pharmaceuticals, Inc. - Common Stock (SPRY) was held by 92 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 55,071,412 shares. The largest 10 holders included DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ORBIMED ADVISORS LLC, FMR LLC, SR ONE CAPITAL MANAGEMENT, LP, RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, BlackRock Inc., BAKER BROS. ADVISORS LP, Nextech Invest Ltd., and VANGUARD GROUP INC. This page lists 92 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.